Matthew Cheung

Where are we after 20 years of R-CHOP in DLBCL?

Update from #ASH21 with the POLARIX trial demonstrating a PFS benefit with pola-R-CHP vs R-CHOP (HR 0.73; p<0.02) but no difference in OS. #lymsm

As we’re about to get access to Paxlovid….remember it’s co-administered with ritonavir for PI-boosting. With heme malignancy drugs, be aware of its CYP3A4 inhibition and use cautiously with venetoclax, ibrutinib, TKIs, anticoagulants, etc.
#lymsm

Always learn so much from Alison Moskowitz - editorial on precision approach to T cell lymphomas ascopubs.org/doi/full/10.12… #lymsm

Congrats to @igong26 @abivije @LisaHicksMD for this extensive summary of COVID vaccine seroresponses and relative benefit (compared to control) in persons with heme malignancies. #lymsm onlinelibrary.wiley.com/doi/full/10.10…

CAR-T in 2L DLBCL - differences in study designs/populations likely explain different outcomes. Thanks to @mana1981 for help with the slide #lymsm #ASH21